Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic subjects

This study was performed to determine whether the levels of soluble intercellular adhesion molecule-1 (sICAM-l) and soluble endothelial molecule-1 (sE-selectin) were elevated in subjects with hypercholesterolemia who presented with no other risk factors or evidence of atherosclerosis. The effects of...

Full description

Saved in:

Bibliographic Details
Published in:	Atherosclerosis Vol. 155; no. 1; pp. 143 - 147
Main Authors:	Sardo, Maria A, Castaldo, Maria, Cinquegrani, Maurizio, Bonaiuto, Michele, Maesano, Antonella, Schepis, Filippo, Zema, Maria C, Campo, Giuseppe M, Squadrito, Francesco, Saitta, Antonino
Format:	Journal Article
Language:	English
Published:	Amsterdam Elsevier Ireland Ltd 01-03-2001 Elsevier
Subjects:	Adult Aged Anticholesteremic Agents - therapeutic use Arteriosclerosis - physiopathology Atherosclerosis Biological and medical sciences Cholesterol - blood E-Selectin - blood Endothelial activation Endothelium, Vascular - physiopathology Female General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Hypercholesterolemia - physiopathology Intercellular Adhesion Molecule-1 - blood Male Medical sciences Middle Aged Pharmacology. Drug treatments sE-Selectin sICAM-1 Simvastatin Simvastatin - therapeutic use sICAM-1 Hypercholesterolemia sE-Selectin Simvastatin Endothelial activation Atherosclerosis Human Prognosis Intercellular adhesion molecule 1 Enzyme E Selectin Hydroxymethylglutaryl-CoA synthase Enzyme inhibitor Metabolic diseases Cholesterol LDL Lipids Hyperlipoproteinemia Lyases Adhesion Oxo-acid-lyases Carbon-carbon lyases Chemotherapy Treatment Dyslipemia Antilipemic agent
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This study was performed to determine whether the levels of soluble intercellular adhesion molecule-1 (sICAM-l) and soluble endothelial molecule-1 (sE-selectin) were elevated in subjects with hypercholesterolemia who presented with no other risk factors or evidence of atherosclerosis. The effects of administration of an HMG-CoA reductase inhibitor on the serum levels of these molecules were also examined. Forty hypercholesterolemic subjects (HCh) (19 males and 21 females), without hypertension or cardiovascular disease, received placebo for 4 weeks. The patients were then randomized in two groups; 20 of them (simvastatin group) were treated with simvastatin (20 mg/day) and the other 20 (placebo group) continued placebo administration. After 12 and 24 weeks of either simvastatin or placebo treatment, sICAM-1 and sE-selectin levels were measured. The same parameters were measured in 20 control subjects (C) with normal cholesterol levels, matched for sex and age. HCh had sICAM-1 basal values higher than C (352.4±57.9 ng/ml versus 114.9±89.6 ng/ml; P<0.001); however, sE-selectin basal values were not different in the two groups. No correlation was observed between HCh sICAM-1 levels and cholesterol levels (total and low-density lipoprotein). Furthermore, cholesterol-lowering treatment with simvastatin did not significantly diminish sICAM-1 levels. Our findings would support the hypothesis that patients with isolated hypercholesterolemia and without clinical atherosclerosis may be silent carriers of arterial subendothelial inflammation, expressed as an increase of sICAM-1.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23
ISSN:	0021-9150 1879-1484
DOI:	10.1016/S0021-9150(00)00520-7